Hung-Sheng Shang1,2, Kuo-Wei Chen3, Jiann-Shang Chou4, Shu-Fen Peng5,6, Yung-Liang Chen7, Po-Yuan Chen5, Hsieh-Chou Huang8,9, Hsu-Feng Lu10,11, Hsin-Yu Chang10, Yung-Luen Shih12,13,14, Wen-Wen Huang15. 1. Graduate Institute of Clinical of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C. 2. Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C. 3. Division of Hematology and Oncology, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C. 4. Department of Anatomic Pathology, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C. 5. Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C. 6. Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C. 7. Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, Taiwan, R.O.C. 8. Anesthesiology and Pain Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C. 9. Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan, R.O.C. 10. Department of Clinical Pathology, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C. 11. Department of Restaurant, Hotel and Institutional Management, Fu-Jen Catholic University, New Taipei, Taiwan, R.O.C. 12. School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan, R.O.C. t005524@ms.skh.org.tw wwhuang@mail.cmu.edu.tw. 13. Department of Pathology and Laboratory Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C. 14. School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, Taiwan, R.O.C. 15. Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C. t005524@ms.skh.org.tw wwhuang@mail.cmu.edu.tw.
Abstract
BACKGROUND/AIM: Casticin, one of the active components of Vitex rotundifolia L., presents biological and pharmacological activities including inhibition of migration, invasion and induction of apoptosis in numerous human cancer cells in vitro. This study aimed to assess the effects of casticin on tumor growth in a human oral cancer SCC-4 cell xenograft mouse model in vivo. MATERIALS AND METHODS: Twenty-four nude mice were injected subcutaneously with SCC-4 cells and when palpable tumors reached a volume of 100-120 mm3 the mice were randomly divided into three groups. The control (0.1% dimethyl sulfoxide), casticin (0.2 mg/kg), and casticin (0.4 mg/kg) groups were intraperitoneally injected every two days for 18 days. Tumor volume and body weights were measured every two days. RESULTS: Casticin significantly decreased tumor volume and weight in SCC-4 cell xenograft mice but there was no statistically significant difference between the body weights of control mice and mice treated with 0.2 mg/kg or 0.4 mg/kg casticin. Therefore, the growth of SCC-4 cells in athymic nude mice can be inhibited by casticin in vivo. CONCLUSION: These findings support further investigations in the potential use of casticin as an oral anti-cancer drug in the future. Copyright
BACKGROUND/AIM: Casticin, one of the active components of Vitex rotundifolia L., presents biological and pharmacological activities including inhibition of migration, invasion and induction of apoptosis in numerous humancancer cells in vitro. This study aimed to assess the effects of casticin on tumor growth in a human oral cancerSCC-4 cell xenograft mouse model in vivo. MATERIALS AND METHODS: Twenty-four nude mice were injected subcutaneously with SCC-4 cells and when palpable tumors reached a volume of 100-120 mm3 the mice were randomly divided into three groups. The control (0.1% dimethyl sulfoxide), casticin (0.2 mg/kg), and casticin (0.4 mg/kg) groups were intraperitoneally injected every two days for 18 days. Tumor volume and body weights were measured every two days. RESULTS:Casticin significantly decreased tumor volume and weight in SCC-4 cell xenograft mice but there was no statistically significant difference between the body weights of control mice and mice treated with 0.2 mg/kg or 0.4 mg/kg casticin. Therefore, the growth of SCC-4 cells in athymic nude mice can be inhibited by casticin in vivo. CONCLUSION: These findings support further investigations in the potential use of casticin as an oral anti-cancer drug in the future. Copyright
Authors: John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt Journal: Nat Rev Clin Oncol Date: 2012-04-17 Impact factor: 66.675